Citius Pharmaceuticals (CTXR) Competitors

InterCure (NASDAQ:INCR) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Which has stronger valuation and earnings, INCR or CTXR?

InterCure has higher revenue and earnings than Citius Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$64.55M	1.10	-$18.32M	N/A	N/A
Citius Pharmaceuticals	N/A	N/A	-$39.14M	N/A	N/A

Is INCR or CTXR more profitable?

InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-58.63%	-37.67%

Do analysts prefer INCR or CTXR?

Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 2,266.07%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Citius Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80

Do institutionals and insiders have more ownership in INCR or CTXR?

8.3% of InterCure shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media favor INCR or CTXR?

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 2 mentions for InterCure. InterCure's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, INCR or CTXR?

InterCure has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Summary

Citius Pharmaceuticals beats InterCure on 8 of the 12 factors compared between the two stocks.